



# indonesia

value of insight

a consulting & publishing company

## **Table of Contents**

<b>Major Events .....</b>	<b>5</b>
<b>Healthcare System .....</b>	<b>6</b>
Health Infrastructure .....	6
Health Insurance .....	7
Universal Health System Status .....	8
<b>Pharmaceutical Market .....</b>	<b>10</b>
Market Profile .....	10
<i>Regulatory Barriers and Market Access</i> .....	13
Market Performance and Forecasts .....	14
<b>Regulatory .....</b>	<b>15</b>
<b>Approval Procedures .....</b>	<b>16</b>
<b>Pricing.....</b>	<b>17</b>
<b>Payment .....</b>	<b>18</b>
PT Askes Formulary (DPHO).....	19
<b>Generics.....</b>	<b>20</b>
<b>R&amp;D / Clinical Trials .....</b>	<b>21</b>
<b>Manufacturing.....</b>	<b>22</b>
<b>Distribution .....</b>	<b>23</b>
<b>Patent &amp; Intellectual Property Issues .....</b>	<b>24</b>
Compulsory Licensing .....	24
<b>Marketing .....</b>	<b>25</b>

## List of Figures

Figure 1 – Population and Economic Statistics .....	5
Figure 2 – General Healthcare Statistics.....	5
Figure 3 – Trends in Public Health Centers (Puskesmas).....	6
Figure 4 – Distribution of Public and Private Hospitals (Aug 2012) .....	7
Figure 5 – Demographic Profile .....	9
Figure 6 - Pharmaceutical Market Snapshot.....	10
Figure 7 - Sales and Share by Product Type 2007-2012 (Ex-manufacturer).....	11
Figure 8 - Leading Prescription and OTC Companies (2011).....	12
Figure 9 - Leading Companies: Overall, Pharmacy, and Hospital Markets (2011) .....	13
Figure 10 - Prescription and OTC Sales Forecasts (2012 to 2016) .....	15
Figure 11 – Structure and Responsibilities within BPOM’s Directorate of Drug & Biological Product Evaluation.....	16
Figure 12 - Characteristics of the DPHO Formulary 2007 to 2012.....	20
Figure 13 – Indonesian Clinical Trial Starts by Phase (Number and Share: 2006-2012).....	22
Figure 14 – Structure of Distribution Network.....	23
Figure 15 - Products covered by compulsory license decree (September 3, 2012).....	24